Literature DB >> 2044227

Reactivity patterns of anti-phospholipid antibodies in systemic lupus erythematosus sera in relation to erythrocyte binding and complement activation.

J Arvieux1, B Roussel, D Ponard, M G Colomb.   

Abstract

We studied 51 sera from patients with systemic lupus erythematosus to determine the relationship of their anti-phospholipid activity to their anti-erythrocyte and complement activation properties. Forty-nine per cent of the sera had anti-phospholipid activity as demonstrated by ELISA using a panel of anionic phospholipids, and most of these also bound to neutral phospholipids, albeit to a lesser extent. A cellular radioimmunoassay was used for the detection of immunoglobulin and C3 binding to normal erythrocytes (intact, enzyme-treated or glutaraldehyde-fixed) following incubation with patient sera. The levels of IgG anti-phospholipid correlated with hypocomplementaemia and with immunoglobulin binding (paralleled by a deposition of C3 fragments) to the three types of erythrocytes, although most strongly to fixed cells. Immunoglobulin binding to intact erythrocytes correlated primarily with reactivity against neutral phospholipids. The specificity for phospholipid epitopes of immunoglobulin adsorbed onto erythrocytes was confirmed by acid elution followed by testing in ELISA. These data suggest that some anti-phospholipid antibody subsets may bind to erythrocytes in vivo, thus accounting for the observed association of these antibodies with positive direct antiglobulin tests.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2044227      PMCID: PMC1535430     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  22 in total

1.  Relationship between anti-DNA antibodies complement consumption and circulating immune complexes in systemic lupus erythematosus.

Authors:  P Davis; R H Cumming; J Verrier-Jones
Journal:  Clin Exp Immunol       Date:  1977-05       Impact factor: 4.330

Review 2.  The red cell membrane.

Authors:  V T Marchesi; H Furthmayr; M Tomita
Journal:  Annu Rev Biochem       Date:  1976       Impact factor: 23.643

3.  Further immunological studies of sera containing anti-mitochondrial antibodies, type M 5.

Authors:  R Norberg; B Gårdlund; R Thorstensson; K Lidman
Journal:  Clin Exp Immunol       Date:  1984-12       Impact factor: 4.330

4.  Thrombosis, recurrent fetal loss, and thrombocytopenia. Predictive value of the anticardiolipin antibody test.

Authors:  E N Harris; J K Chan; R A Asherson; V R Aber; A E Gharavi; G R Hughes
Journal:  Arch Intern Med       Date:  1986-11

5.  The 1982 revised criteria for the classification of systemic lupus erythematosus.

Authors:  E M Tan; A S Cohen; J F Fries; A T Masi; D J McShane; N F Rothfield; J G Schaller; N Talal; R J Winchester
Journal:  Arthritis Rheum       Date:  1982-11

6.  Immunology of DNA. III. Crithidia luciliae, a simple substrate for the determination of anti-dsDNA with the immunofluorescence technique.

Authors:  L A Aarden; E R de Groot; T E Feltkamp
Journal:  Ann N Y Acad Sci       Date:  1975-06-30       Impact factor: 5.691

7.  Human hybridoma lupus anticoagulants distinguish between lamellar and hexagonal phase lipid systems.

Authors:  J Rauch; M Tannenbaum; H Tannenbaum; H Ramelson; P R Cullis; C P Tilcock; M J Hope; A S Janoff
Journal:  J Biol Chem       Date:  1986-07-25       Impact factor: 5.157

8.  Detection of circulating immune complexes in pathological human sera.

Authors:  A H Johnson; J F Mowbray; K A Porter
Journal:  Lancet       Date:  1975-04-05       Impact factor: 79.321

9.  Disease-associated loss of erythrocyte complement receptors (CR1, C3b receptors) in patients with systemic lupus erythematosus and other diseases involving autoantibodies and/or complement activation.

Authors:  G D Ross; W J Yount; M J Walport; J B Winfield; C J Parker; C R Fuller; R P Taylor; B L Myones; P J Lachmann
Journal:  J Immunol       Date:  1985-09       Impact factor: 5.422

10.  Anti-phospholipid antibodies and biological false positive serological test for syphilis in patients with systemic lupus erythematosus.

Authors:  T Koike; M Sueishi; H Funaki; H Tomioka; S Yoshida
Journal:  Clin Exp Immunol       Date:  1984-04       Impact factor: 4.330

View more
  5 in total

1.  Anaemia in systemic lupus erythematosus: aetiological profile and the role of erythropoietin.

Authors:  M Voulgarelis; S I Kokori; J P Ioannidis; A G Tzioufas; D Kyriaki; H M Moutsopoulos
Journal:  Ann Rheum Dis       Date:  2000-03       Impact factor: 19.103

2.  High levels of anti-phospholipid antibodies in uncomplicated and severe Plasmodium falciparum and in P. vivax malaria.

Authors:  C A Facer; G Agiostratidou
Journal:  Clin Exp Immunol       Date:  1994-02       Impact factor: 4.330

3.  Anti-phospholipid antibodies in patients with Plasmodium falciparum malaria.

Authors:  P H Jakobsen; S D Morris-Jones; L Hviid; T G Theander; M Høier-Madsen; R A Bayoumi; B M Greenwood
Journal:  Immunology       Date:  1993-08       Impact factor: 7.397

4.  Histones interact with anionic phospholipids with high avidity; its relevance for the binding of histone-antihistone immune complexes.

Authors:  L F Pereira; F M Marco; R Boimorto; A Caturla; A Bustos; E G De la Concha; J L Subiza
Journal:  Clin Exp Immunol       Date:  1994-08       Impact factor: 4.330

5.  Immunoglobulin class and IgG subclass distribution of anticardiolipin antibodies in patients with systemic lupus erythematosus and associated disorders.

Authors:  S Loizou; C Cofiner; A P Weetman; M J Walport
Journal:  Clin Exp Immunol       Date:  1992-12       Impact factor: 4.330

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.